ProfileGDS5678 / 1454373_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 81% 81% 81% 79% 79% 87% 83% 79% 83% 81% 85% 80% 81% 81% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.8102681
GSM967853U87-EV human glioblastoma xenograft - Control 25.7898281
GSM967854U87-EV human glioblastoma xenograft - Control 35.8665181
GSM967855U87-EV human glioblastoma xenograft - Control 45.70479
GSM967856U87-EV human glioblastoma xenograft - Control 55.5075479
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.4476587
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.898783
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.5276879
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.0073883
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.7873881
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.3314785
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.6952180
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.7995781
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.7918981